SCHEMBL411034

SCHEMBL411034

CC(C)[Si](C(C)C)(C(C)C)C(c1c[nH]c2ncccc12)N(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.45
GPR84 Q9NQS5 1/20 0.44
DYRK1A Q13627 1/20 0.44
MET P08581 6/20 0.42
LRRK2 Q5S007 1/20 0.42
KMT2A Q03164 1/20 0.42
MAP2K1 Q02750 1/20 0.41
SLC6A4 P31645 1/20 0.41
PDPK1 O15530 1/20 0.38
TGFBR1 P36897 1/20 0.38
IKBKE Q14164 1/20 0.38
GRM8 O00222 1/20 0.38
GRM4 Q14833 1/20 0.38
FGFR1 P11362 1/20 0.38
FGFR4 P22455 1/20 0.38
MTNR1A P48039 1/20 0.37
BRD4 O60885 1/20 0.37
CDC7 O00311 2/20 0.37
CCNE1 P24864 2/20 0.37
CDK2 P24941 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9046899 0.83 AXL (0.49) AXLGPR84DYRK1AMETLRRK2
SCHEMBL30068926 0.79 AXL (0.55) AXLGPR84DYRK1AMETLRRK2
SCHEMBL820352 0.79 AXL (0.55) AXLGPR84DYRK1AMETLRRK2
SCHEMBL27590571 0.76 AXL (0.51) AXLGPR84DYRK1AMETLRRK2
SCHEMBL12491066 0.76 AXL (0.51) AXLGPR84DYRK1AMETLRRK2
SCHEMBL21912529 0.76 AXL (0.51) AXLGPR84DYRK1AMETLRRK2
SCHEMBL22430456 0.76 AXL (0.51) AXLGPR84DYRK1AMETLRRK2
SCHEMBL15091645 0.76 MET (0.46) AXLGPR84DYRK1AMETLRRK2
SCHEMBL413118 0.74 AXL (0.40) AXLGPR84DYRK1AMETLRRK2
SCHEMBL26176435 0.74 GPR84 (0.51) AXLGPR84DYRK1AMETLRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190263800-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON INC. 2019-08-29 US disclosed
US-20180111929-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC (US) 2018-04-26 US disclosed
US-20170247370-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON INC. 2017-08-31 US disclosed
US-9487515-B2 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC. (US) 2016-11-08 US disclosed
EP-3088400-A1 PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS PLEXXIKON INC. (US) 2016-11-02 EP disclosed
US-20160176865-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC (US) 2016-06-23 US disclosed
EP-2395004-B1 Pyrrolo [2,3-b]pyridine derivatives as protein kinase inhibitors PLEXXIKON INC (US) 2016-01-20 EP disclosed
US-20150290205-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC (US) 2015-10-15 US disclosed
US-20150265586-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR DAIICHI SANKYO, INC. 2015-09-24 US disclosed
US-20130303534-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2013-11-14 US disclosed
US-20090076046-A1 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC 2009-03-19 US disclosed
US-7498342-B2 Compounds modulating c-kit activity PLEXXIKON, INC. (US) 2009-03-03 US disclosed
EP-1893612-A1 PYRROLO [2, 3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS PLEXXIKON, INC. (US) 2008-03-05 EP disclosed
EP-1755597-A2 AZAINDOLES MODULATING C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON, INC. (US) 2007-02-28 EP disclosed
US-20070032519-A1 Compounds modulating c-kit and c-fms activity and uses therefor PLEXXIKON, INC. 2007-02-08 US disclosed
WO-2007002433-A1 PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS PLEXXIKON, INC. (US) 2007-01-04 WO disclosed
US-20060058340-A1 Compounds modulating c-kit activity PLEXXIKON INC. 2006-03-16 US disclosed
US-20060058339-A1 Compounds modulating c-kit activity and uses therefor PLEXXIKON, INC. 2006-03-16 US disclosed
WO-2006009755-A2 AZAINDOLES MODULATING C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON, INC. (US) 2006-01-26 WO disclosed
WO-2006009797-A1 AZAINDOLES MODULATING C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON, INC. (US) 2006-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170247370-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 AXL 330/4885GPR84 211/4885DYRK1A 3201/4885
US-20090076046-A1 Compounds modulating c-fms and/or c-kit activity and uses therefor KIT, FLT3, FLT1 AXL 330/4885GPR84 211/4885DYRK1A 3201/4885
US-20180111929-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, MAP3K13, MAP3K8 AXL 1354/4885GPR84 4039/4885DYRK1A 604/4885
US-20060058340-A1 Compounds modulating c-kit activity KIT, CDC7, CDK7 AXL 897/4885GPR84 333/4885DYRK1A 1356/4885
US-20130303534-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, MAP3K13, MAP3K8 AXL 1354/4885GPR84 4039/4885DYRK1A 604/4885
US-20150290205-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, MAP3K13, MAP3K8 AXL 1354/4885GPR84 4039/4885DYRK1A 604/4885
US-20160176865-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, MAP3K13, MAP3K8 AXL 1354/4885GPR84 4039/4885DYRK1A 604/4885
US-20150265586-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 AXL 330/4885GPR84 211/4885DYRK1A 3201/4885
US-20190263800-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 AXL 319/4885GPR84 228/4885DYRK1A 3186/4885
US-20060058339-A1 Compounds modulating c-kit activity and uses therefor KIT, APC, RET AXL 845/4885GPR84 400/4885DYRK1A 1716/4885
US-20070032519-A1 Compounds modulating c-kit and c-fms activity and uses therefor KIT, FLT3, FLT1 AXL 227/4885GPR84 191/4885DYRK1A 2997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.